NASDAQ · MBIO
Mustang Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MBIO: Nov 6, 2026
Mustang Bio, Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.07.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Quiver Quantitative · RTTNews- Zacks · Jul 8, 10:38 AM EDTMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer TherapyMustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
- Quiver Quantitative · Jul 7, 8:43 AM EDTMustang Bio Announces FDA Orphan Drug Designation for MB-101 in Treatment of Recurrent Glioblastoma and High-Grade AstrocytomasMustang Bio's MB-101 receives Orphan Drug Designation, showing promising results in glioma treatment trials.
- RTTNews · Mar 5, 9:49 PM ESTMustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy Advancements(RTTNews) – Mustang Bio, Inc. (MBIO) has announced that it has regained compliance with Nasdaq's minimum stockholders' equity requirement, ensuring that its common stock will continue to be listed on The Nasdaq Capital Market.
- Quiver Quantitative · Mar 5, 4:22 PM ESTMustang Bio, Inc. Regains Compliance with Nasdaq Capital Market Listing RequirementsMustang Bio has regained compliance with Nasdaq's minimum stockholders' equity and bid price requirements for continued listing.
- RTTNews · Feb 28, 6:31 AM ESTMustang Bio Exits Facility And Sells Fixed Assets To AbbVie, Focusing On Advancing Clinical Trials(RTTNews) – Mustang Bio, Inc. (MBIO), on Friday announced that it has exited its lease for the manufacturing facility in Worcester, Massachusetts, and sold certain fixed assets, including furniture and equipment, to AbbVie Bioresearch Center Inc. for $1.0 million.
- Quiver Quantitative · Feb 27, 4:13 PM ESTMustang Bio, Inc. Announces Lease Exit and Asset Divestment to AbbVie for $1 MillionMustang Bio divests its Worcester facility to AbbVie for $1 million and relocates headquarters to Waltham, anticipating $2 million savings.
- Quiver Quantitative · Feb 11, 4:23 PM ESTMustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public OfferingMustang Bio reports regaining Nasdaq compliance and meeting stockholders' equity requirements after a recent public offering.
- Quiver Quantitative · Feb 10, 8:13 AM ESTMustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy DevelopmentMustang Bio closes public offering, raising approximately $8 million for cancer cell therapy development and corporate purposes.
- RTTNews · Feb 6, 1:30 PM ESTMustang Bio Prices $8 Mln Public Offering(RTTNews) – Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company, on Thursday has priced its public offering of 2.66 million shares of its common stock at $3.00 per share, along with Series C-1 and C-2 warrants to purchase the same number of shares at the same pri
- RTTNews · Feb 6, 8:32 AM ESTMustang Bio Prices Public Offering Of 2.65 Mln At $3.01/shr; Stock Down In Pre-market(RTTNews) – Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company, Thursday announced the pricing of a public offering of 2.65 million common shares, expected to close around February 7.
- Quiver Quantitative · Feb 6, 7:13 AM ESTMustang Bio, Inc. Announces $8 Million Public Offering of Common Stock and WarrantsMustang Bio announced a public offering of 2.65 million shares at $3.01 each, aiming to raise approximately $8 million.
- RTTNews · Jan 14, 9:03 AM ESTMustang Bio Sets 1-for-50 Reverse Stock Split(RTTNews) – Mustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company, Tuesday announced its plan for a 1-for-50 reverse stock split.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Mustang Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.